Scholarlink

Background and Objectives <p>Usual treatment approaches for late-life depression primarily involve selective serotonin reuptake inhibitors (SSRIs). Recently, the potential role of vortioxetine has garnered attention. This study aimed to investigate whether vortioxetine is superior to SSRIs in terms of efficacy and tolerability in older people with moderate-to-severe depression. </p> Methods <p>The Vortioxetine in the Elderly versus SSRIs: a Pragmatic Assessment (VESPA) study was an assessor-blinded, randomized, parallel-group, superiority trial, comparing flexible doses of vortioxetine versus SSRIs in older adults with depression. This is a post-hoc analysis that excluded participants with milder symptoms of depression. The primary outcome was the change in Montgomery–Åsberg Depression Rating Scale (MADRS) scores. Secondary outcomes included clinical response (MADRS total score reduction of ≥ 50%), remission (a MADRS score &lt; 10), and discontinuation rates. Clinical measures were conducted at baseline and at 1-month, 3-month, and 6-month (endpoint) visits.</p> Results <p>In total, 302 individuals (mean age: 73.4 ± 5.9 years; 68.9% females), comprising 152 randomized to vortioxetine and 150 to SSRIs (sertraline <i>N</i> = 92; paroxetine <i>N</i> = 19; escitalopram <i>N</i> = 19; citalopram <i>N</i> = 16; fluoxetine <i>N</i> = 3; fluvoxamine <i>N</i> = 1), were included in this post-hoc analysis. No significant differences in MADRS improvement between vortioxetine and SSRIs were observed at any follow-up visits and 6-month endpoint (−11.8 ± 10.6 versus −14.0 ± 11.6; <i>p</i> = 0.12). This was further confirmed by a subgroup analysis excluding drug discontinuers (−16.8 ± 9.0 versus −17.6 ± 10.3; <i>p</i> = 0.51). In addition, people treated with vortioxetine did not exhibit better rates of response (44.1 versus 53.0%; <i>p</i> = 0.11), remission (25.7 versus 34.7%; <i>p</i> = 0.09), and discontinuation (38.0 versus 30.2%; <i>p</i> = 0.17), including discontinuation owing to either side effects or inefficacy, compared with those treated with SSRIs.</p> Conclusions <p>Vortioxetine was not superior to SSRIs in terms of efficacy and tolerability in older adults with moderate-to-severe depression. Additional trials, possibly based on fixed doses of vortioxetine, are needed.</p> Registration <p>Clinicaltrials.gov: NCT03779789, registered on 12 Dec 2018; EudraCT number: 2018-001444-66.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy and Tolerability of Vortioxetine Versus Selective Serotonin Reuptake Inhibitors for Late-Life Depression: A Post-hoc Analysis of the VESPA Study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月18日

查看全文
  • Francesco Bartoli,
  • Daniele Cavaleri,
  • Ilaria Riboldi,
  • Tommaso Callovini,
  • Cristina Crocamo,
  • Chiara Gastaldon,
  • Andrea Aguglia,
  • Camilla Callegari,
  • Simone Cavallotti,
  • Stefania Chiappini,
  • Marco Cruciata,
  • Armando D’Agostino,
  • Irene Espa,
  • Luigi Grassi,
  • Marta Ielmini,
  • Silvia Mammarella,
  • Giovanni Martinotti,
  • Marianna Rania,
  • Alessandro Rodolico,
  • Rita Roncone,
  • Valentina Roselli,
  • Cristina Segura-Garcia,
  • Maria Salvina Signorelli,
  • Lorenzo Tarsitani,
  • Giovanni Ostuzzi,
  • Giuseppe Carrà

摘要

Background and Objectives

Usual treatment approaches for late-life depression primarily involve selective serotonin reuptake inhibitors (SSRIs). Recently, the potential role of vortioxetine has garnered attention. This study aimed to investigate whether vortioxetine is superior to SSRIs in terms of efficacy and tolerability in older people with moderate-to-severe depression.

Methods

The Vortioxetine in the Elderly versus SSRIs: a Pragmatic Assessment (VESPA) study was an assessor-blinded, randomized, parallel-group, superiority trial, comparing flexible doses of vortioxetine versus SSRIs in older adults with depression. This is a post-hoc analysis that excluded participants with milder symptoms of depression. The primary outcome was the change in Montgomery–Åsberg Depression Rating Scale (MADRS) scores. Secondary outcomes included clinical response (MADRS total score reduction of ≥ 50%), remission (a MADRS score < 10), and discontinuation rates. Clinical measures were conducted at baseline and at 1-month, 3-month, and 6-month (endpoint) visits.

Results

In total, 302 individuals (mean age: 73.4 ± 5.9 years; 68.9% females), comprising 152 randomized to vortioxetine and 150 to SSRIs (sertraline N = 92; paroxetine N = 19; escitalopram N = 19; citalopram N = 16; fluoxetine N = 3; fluvoxamine N = 1), were included in this post-hoc analysis. No significant differences in MADRS improvement between vortioxetine and SSRIs were observed at any follow-up visits and 6-month endpoint (−11.8 ± 10.6 versus −14.0 ± 11.6; p = 0.12). This was further confirmed by a subgroup analysis excluding drug discontinuers (−16.8 ± 9.0 versus −17.6 ± 10.3; p = 0.51). In addition, people treated with vortioxetine did not exhibit better rates of response (44.1 versus 53.0%; p = 0.11), remission (25.7 versus 34.7%; p = 0.09), and discontinuation (38.0 versus 30.2%; p = 0.17), including discontinuation owing to either side effects or inefficacy, compared with those treated with SSRIs.

Conclusions

Vortioxetine was not superior to SSRIs in terms of efficacy and tolerability in older adults with moderate-to-severe depression. Additional trials, possibly based on fixed doses of vortioxetine, are needed.

Registration

Clinicaltrials.gov: NCT03779789, registered on 12 Dec 2018; EudraCT number: 2018-001444-66.